Skip to content
Learn Motion
ExploreHow it worksPricing

Download Learn Motion

Scan the QR code with your phone to install the app.

App Store

Scan to download Learn Motion from the App StoreOpen store page

Google Play

Scan to download Learn Motion from Google PlayOpen store page
Log in
Learn Motion

How Antibiotics Kill Bacteria and Why Resistance Develops

1Bacterial Targets: What Makes a Good Antibiotic Target2How Major Antibiotic Classes Kill Bacteria3Genetic Origins of Resistance: Mutation and Horizontal Gene Transfer4Biochemical Mechanisms of Resistance5Multidrug Resistance, Co-selection, and Clinical Consequences
Multidrug Resistance, Co-selection, and Clinical Consequences

Fitness Costs, Co-selection, and Collateral Sensitivity

2 / 3
So why don't those costly defenses simply disappear once the antibiotic is gone? Zoom out from that one multidrug-resistant cell to the whole population, and the answer starts to appear. In a drug-free environment, the susceptible cells divide faster, because they aren't paying the price of replicating a plasmid or powering an efflux pump. Run the two populations side by side and the resistant subpopulation shrinks — that growth penalty is the fitness cost of resistance. It's the reason resistance can fade after a drug is withdrawn.
0:00 / 0:00

Why resistance often costs fitness
A resistance determinant is an extra burden: a plasmid must be replicated, a pump must be powered, an altered target may work less efficiently. In a drug-free environment the susceptible competitor usually grows faster, so resistant cells are outcompeted. This is why resistance can fall after an antibiotic is withdrawn — but compensatory mutations can restore fitness while keeping the resistance gene, so the decline is often partial and sometimes absent.
Co-selection: one drug, several resistances
When resistance genes are genetically linked on the same plasmid, transposon, or integron, selecting for one gene selects for all of them. The same happens when a single efflux pump exports two different antibiotics. The practical consequence is that using one antibiotic can maintain resistance to unrelated drugs that are not being used.
Collateral sensitivity: the reciprocal trade-off
Sometimes evolving resistance to drug A increases susceptibility to drug B. The resistance mechanism — for example, a change in membrane permeability or efflux capacity — can make the cell more vulnerable to a drug it has not encountered. If the trade-off is reliable, alternating or combining drugs could exploit it, but the effect depends on the specific mechanism and drug pair and is not yet a settled clinical rule.

References

  1. [1]The fitness costs of antibiotic resistancenature.com
  2. [2]Collateral sensitivity as a strategy against antibiotic resistancenature.com
Previous2 / 3Next

Learn Motion

Generate a course. Learn it properly.

Operated by Wuhan Daoyin Technology Co., Ltd.

Contact: [email protected]
Privacy PolicyTerms of Service

© 2026 Learn Motion